June 09, 2025 a 05:01 pm
JNJ: Analysts Ratings - Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) continues to perform steadily in the healthcare sector, with diverse operations across consumer health, pharmaceuticals, and medical devices. Despite global economic challenges, the company's commitment to innovation allows it to maintain a competitive edge. Analyst ratings indicate a mixed sentiment, with a dominance of Hold recommendations, suggesting a cautious but stable market outlook.
Historical Stock Grades
Analyzing the latest data from June 2025, Johnson & Johnson has received a total of 24 ratings. There has been a consistent preference for Hold ratings, reflecting a conservative stance from investors, while Buy recommendations slightly outnumber Strong Buy ratings. The absence of Sell and Strong Sell ratings highlights a prevailing belief in the stock’s resilience.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 7 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for Johnson & Johnson has shown a consistent pattern with a stable number of ratings. The Hold category has remained dominant, reflecting a risk-averse approach from analysts. Notable observations include:
- The total number of ratings has seen minor fluctuations, indicating a stable interest in JNJ stock.
- Strong Buy recommendations have experienced minimal changes, maintaining a steady level.
- An increase in Hold ratings suggests some analysts prefer a cautious stance amidst uncertain market conditions.
Percentage Trends
Observing percentage trends highlights a subtle yet impactful shift in analyst sentiment. Key points include:
- Hold recommendations have gradually increased, now representing over half of all ratings, indicating growing caution.
- Buy ratings have seen a slight decline in percentage terms, potentially due to changing market dynamics.
- Overall, there is a visible trend towards more conservative recommendations, reflecting cautious optimism about future growth prospects.
Latest Analyst Recommendations
Recent analyst activity for JNJ shows a mix of maintained and downgraded ratings, reflecting varied perspectives on the company's outlook. Here are the latest recommendations:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-05 | Outperform | Outperform | RBC Capital |
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-17 | Equal Weight | Equal Weight | Barclays |
| 2025-04-16 | Outperform | Outperform | RBC Capital |
| 2025-04-16 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Changes in analyst opinions provide insight into shifts in market sentiment. Notable changes include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-09 | Buy | Neutral | Goldman Sachs |
| 2024-07-23 | Neutral | Outperform | Daiwa Capital |
| 2024-04-18 | Buy | Hold | HSBC |
| 2023-12-13 | Equal Weight | Overweight | Wells Fargo |
Interpretation
The latest analyst ratings for Johnson & Johnson suggest a sustained level of caution with a stable base of Hold recommendations. The increase in Hold ratings and downgrades from Outperform to Market Perform or Neutral highlight some concerns about future growth potential. Despite such reservations, the lack of Sell ratings points to a general confidence in the company’s long-term resilience.
Conclusion
Johnson & Johnson's current analyst ratings demonstrate a conservative but stable sentiment among analysts. The growing number of Hold recommendations suggests caution amidst economic uncertainties, while the decrease in Strong Buy and Buy ratings signals consideration of possible risks. However, the absence of negative ratings (Sell/Strong Sell) underscores confidence in JNJ’s diverse portfolio and market position. Analysts are likely to continue closely monitoring macroeconomic factors impacting the healthcare industry.